What is the current reference price of sparsentan/sparsentan?

Sparsentan is a new type of dual receptor antagonist that has the dual action mechanism of angiotensin II receptor blocker (ARB) and endothelin receptor antagonist (ERA). It is mainly used to treat refractory kidney diseases, such as primary immunoglobulin A nephropathy. Although the drug has been approved for marketing in overseas markets, it has not yet entered the domestic market, so its domestic price has not yet been determined. Patients mainly rely on overseas imports for purchase, and the price is relatively high.

According to public information, the main sales specifications of Sparsentane in the European and American markets are200mg and 400mg tablets, with each box containing 30 tablets. Because of its status as an innovative drug and its complex research and development process, its price positioning is relatively high, with each box generally selling for more than RMB 40,000. The price reflects the drug’s higher R&D investment and patent protection period, and is consistent with its clinical value. The specific value of the price will also be affected by exchange rate changes, local medical insurance policies and distribution channels, so there will be some fluctuation.

At the same time, as the global generic drug market continues to expand, generic versions of Sparsentan have appeared in some countries. These generic drugs are basically the same as the original drugs in terms of ingredients and dosage, and their quality is guaranteed. However, due to different production costs and sales strategies, the prices have been significantly reduced. For example, a generic drug of 400mg*30 tablets produced by a pharmaceutical factory in Laos is sold in overseas markets for only more than 3,000 yuan, which is more than ten times lower than the price of the original drug, which greatly alleviates the financial pressure on patients.

At present, sparsentin is not yet on the market in China and is not included in medical insurance. If patients need the medicine, they need to import it through formal overseas channels, and the price has increased due to factors such as transportation, taxes, and middleman fees. In the future, with the advancement of domestic approval procedures and investment in the research and development of generic drugs, the price of sparsentan is expected to gradually decrease, improving patient accessibility and allowing more kidney disease patients to benefit from this innovative drug.

Reference materials:https://www.sparsentan.com/